Year All20242023202220212020201920182017 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 06, 2023 Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023 Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Aug 08, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2023 Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock Aug 01, 2023 Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock Jul 27, 2023 Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock Jul 27, 2023 Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 26, 2023 Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023 Jul 19, 2023 Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 Jun 27, 2023
Year All20242023202220212020201920182017 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 06, 2023 Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023 Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Aug 08, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2023 Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock Aug 01, 2023 Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock Jul 27, 2023 Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock Jul 27, 2023 Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 26, 2023 Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023 Jul 19, 2023 Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 Jun 27, 2023
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Aug 08, 2023
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 26, 2023
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 Jun 27, 2023